Impact of Maternal Body Mass Index on Infant Hypoxic Events at Time of Delivery ,Cross-sectional Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Esraa Hussein, master
- Phone Number: 01008057054
- Email: esraaghoneimy81@gmail.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age of 18 - 40 years.
- Term pregnancy (37 weeks gestation or more)
- Singleton pregnancy
- Cephalic presentation at time of delivery
- In labour
Exclusion Criteria:
- Any medical disorders that affect neonatal outcomes (diabetes mellitus, hypertension, mixed connective tissue disorders)
- Scarred uterus (myomectomy, previous cesarean section)
- Macrosomic baby>4 kgs
- Condition jeopardizing the maternal or fetal life (for example: antepartum hemorrhage, pathological CTG, cord prolapse)
- Liquor abnormalities (oligohydramnios or polyhydramnios).
- Other indications for cesarean sections for example: placenta accreta spectrum
- Smokers.
- Any abnormalities in follow up of delivery regarding partogram.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
group A (case group )
women with body mass index equal to 25 kg/m2 or more at time of delivery.
|
early neonatal resuscitation will be done by the pediatrician according to the guidelines, APGAR score of the baby will be calculated,, any hypoxic events will be traced and any need of respiratory support for the baby or NICU admission, as well as weight of the baby, mode of delivery and any birth traumas will be recorded.all
this will be compared between two groups.
|
|
group B ( control group )
women with body mass index (18.5-24.9
kg/m2) at time of delivery
|
early neonatal resuscitation will be done by the pediatrician according to the guidelines, APGAR score of the baby will be calculated,, any hypoxic events will be traced and any need of respiratory support for the baby or NICU admission, as well as weight of the baby, mode of delivery and any birth traumas will be recorded.all
this will be compared between two groups.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of admission to neonatal observation room
Time Frame: 6 hours post delivery
|
6 hours post delivery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of cesarean-sections.
Time Frame: 12 hours
|
12 hours
|
|
Oxygen saturation at birth.
Time Frame: 2 hours post delivery
|
2 hours post delivery
|
|
Number of babies with NICU Admission.
Time Frame: 6 hours post delivery
|
6 hours post delivery
|
|
Number of babies with birth trauma.
Time Frame: 2 hours post delivery
|
2 hours post delivery
|
|
Number of babies with meconium aspiration.
Time Frame: 2 hours post delivery
|
2 hours post delivery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MD344/2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Maternal Obesity
-
NCT03307733CompletedMaternal Obesity Complicating Pregnancy | Maternal Obesity Complicating Childbirth
-
NCT01514539CompletedMaternal Obesity Syndrome
-
NCT03240419CompletedInflammation | Insulin Resistance | Childhood Obesity | Maternal Obesity During Childbirth
-
NCT04093479CompletedMaternal Obesity During Childbirth | Labor; Arrested Active Phase
-
NCT02766426UnknownExercise Addiction | Maternal Obesity Complicating Pregnancy | High-Risk Pregnancy | Inflammatory Status During Preganancy | Maternal Body Composition
-
NCT03084120Unknown
-
NCT05475951CompletedPregnancy Complications | Maternal Obesity
-
NCT03913364Unknown
-
NCT05986539RecruitingMaternal Behavior | Infant Development | Maternal Obesity | Breast Milk Collection
Clinical Trials on compare infant hypoxic events in both groups
-
NCT01496482Completed
-
NCT03129308CompletedHIV Infections | Autoimmune Diseases Affecting Skin
-
NCT01485237CompletedNovel H1N1 Influenzal Acute Respiratory Infection
-
NCT06530355CompletedFunction | Hand | Piano Therapy
-
NCT07629388Not yet recruitingPain Management | Pain After Total Knee Arthroplasty
-
NCT01577316UnknownPregnancy | Investigation or Care in A Nonpregnant Woman
-
NCT02288702Terminated